BibTex format
@article{Prendecki:2021:10.1136/annrheumdis-2021-220626,
author = {Prendecki, M and Clarke, C and Edwards, H and McIntyre, S and Mortimer, P and Gleeson, S and Martin, P and Thomson, T and Randell, P and Shah, A and Singanayagam, A and Lightstone, L and Cox, A and Kelleher, P and Willicombe, M and McAdoo, SP},
doi = {10.1136/annrheumdis-2021-220626},
journal = {Annals of the Rheumatic Diseases},
pages = {1322--1329},
title = {Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.},
url = {http://dx.doi.org/10.1136/annrheumdis-2021-220626},
volume = {80},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - OBJECTIVE: There is an urgent need to assess the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination. METHODS: Serological and T-cell ELISpot assays were used to assess the response to first-dose and second-dose SARS-CoV-2 vaccine (with either BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccines) in 140 participants receiving immunosuppression for autoimmune rheumatic and glomerular diseases. RESULTS: Following first-dose vaccine, 28.6% (34/119) of infection-naïve participants seroconverted and 26.0% (13/50) had detectable T-cell responses to SARS-CoV-2. Immune responses were augmented by second-dose vaccine, increasing seroconversion and T-cell response rates to 59.3% (54/91) and 82.6% (38/46), respectively. B-cell depletion at the time of vaccination was associated with failure to seroconvert, and tacrolimus therapy was associated with diminished T-cell responses. Reassuringly, only 8.7% of infection-naïve patients had neither antibody nor T-cell responses detected following second-dose vaccine. In patients with evidence of prior SARS-CoV-2 infection (19/140), all mounted high-titre antibody responses after first-dose vaccine, regardless of immunosuppressive therapy. CONCLUSION: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, when assessed by a combination of serology and cell-based assays, although the response is impaired compared with healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. We suggest that repeat vaccine doses for serological non-responders should be investigated as means to induce more robust immunological response.
AU - Prendecki,M
AU - Clarke,C
AU - Edwards,H
AU - McIntyre,S
AU - Mortimer,P
AU - Gleeson,S
AU - Martin,P
AU - Thomson,T
AU - Randell,P
AU - Shah,A
AU - Singanayagam,A
AU - Lightstone,L
AU - Cox,A
AU - Kelleher,P
AU - Willicombe,M
AU - McAdoo,SP
DO - 10.1136/annrheumdis-2021-220626
EP - 1329
PY - 2021///
SN - 0003-4967
SP - 1322
TI - Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
T2 - Annals of the Rheumatic Diseases
UR - http://dx.doi.org/10.1136/annrheumdis-2021-220626
UR - https://www.ncbi.nlm.nih.gov/pubmed/34362747
UR - https://ard.bmj.com/content/80/10/1322
UR - http://hdl.handle.net/10044/1/91658
VL - 80
ER -
